US CDC panel recommends Sanofi-AstraZeneca's preventive RSV therapy for
babies
Send a link to a friend
[August 04, 2023]
(Reuters) -The U.S. Centers for Disease Control and Prevention
(CDC) said its advisory panel on Thursday recommended use of Sanofi and
partner AstraZeneca's antibody therapy to prevent respiratory syncytial
virus (RSV) in infants and toddlers.
The Advisory Committee on Immunization Practices unanimously recommended
nirsevimab for preventing lower respiratory tract disease in newborns
and infants below eight months of age born during or entering their
first RSV season.
It also recommended its use in children aged 8-19 months who remain
vulnerable to severe RSV disease through their second such season.
The therapy, branded as Beyfortus, will be available in the U.S. ahead
of the upcoming 2023-24 RSV season, Sanofi said.
[to top of second column]
|
AstraZeneca's site in Macclesfield,
Britain, May 11, 2021. REUTERS/Phil Noble/File Photo
The U.S. Food and Drug
Administration had last month approved the long-acting therapy that
can be given once every season to prevent infection regardless of
additional medical conditions in infants.
(Reporting by Mrinmay Dey and Mariam Sunny in Bengaluru)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |